Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neurogenic locus notch homolog protein 1 (NOTCH1) is a single-pass transmembrane receptor that serves as a critical mediator of cell-to-cell communication and cell fate determination (UniProt Consortium, 2024). Upon binding to ligands such as Delta-like or Jagged on adjacent cells, NOTCH1 undergoes sequential proteolytic cleavages, culminating in the release of the Notch intracellular domain (NICD) by the gamma-secretase complex (Siebel & Lendahl, 2017). The NICD then translocates to the nucleus, where it associates with the DNA-binding protein RBPJ to activate the transcription of target genes like HES1 and MYC, which regulate cell proliferation and differentiation (Aster et al., 2017). Dysregulation of NOTCH1 signaling is a primary driver in various malignancies, most notably T-cell acute lymphoblastic leukemia (T-ALL), where activating mutations are found in over 50% of cases (Weng et al., 2004). Therapeutic interventions primarily focus on gamma-secretase inhibitors (GSIs) and monoclonal antibodies designed to block receptor activation or ligand binding (Takebe et al., 2014). However, the clinical development of these agents has been significantly challenged by dose-limiting gastrointestinal toxicity, resulting from the essential role of NOTCH1 in maintaining the balance between secretory and absorptive cells in the intestinal epithelium (van Es et al., 2005).
Inhibition of the gamma-secretase complex to prevent the release of the Notch intracellular domain (NICD), or use of monoclonal antibodies to block ligand binding or receptor activation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neurogenic locus notch homolog protein 1 (NOTCH1) (NOTCH1).